Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study

Abstract Background Icatibant is a bradykinin B2-receptor antagonist used for the treatment of hereditary angioedema attacks resulting from C1-inhibitor deficiency. Treatment is not adjusted by body weight however the impact of body mass index (BMI) on the effectiveness of icatibant is not documente...

Full description

Bibliographic Details
Main Authors: Teresa Caballero, Andrea Zanichelli, Werner Aberer, Marcus Maurer, Hilary J. Longhurst, Laurence Bouillet, Irmgard Andresen, the IOS Study Group
Format: Article
Language:English
Published: Wiley 2018-03-01
Series:Clinical and Translational Allergy
Subjects:
Hereditary angioedema
Icatibant
Bradykinin
Body mass index
Online Access:http://link.springer.com/article/10.1186/s13601-018-0195-x

Internet

http://link.springer.com/article/10.1186/s13601-018-0195-x

Similar Items